Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI-3037MO in Severe Hypertriglyceridemia
NCT02250105Phase 2Completed
- Sponsor
- Arisaph Pharmaceuticals
- Start
- Sep 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ARI-3037MO in hypertriglyceridemia, sponsored by Arisaph Pharmaceuticals. Started Sep 2014; status: completed.
02
Drugs
ARI-3037MO
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT02250105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250105.